


Amendments to the Claims

The following listing of claims shall replace all prior versions, or listings of claims in this application.

Listing of Claims:

1. (Currently Amended) ~~Method~~ A method for the preparation of 2'- or 3'-deoxy- and 2',3'-dideoxy- β -L-pentofurano[[c]]nucleoside compounds of formula I:




in which

- B represents purine or pyrimidine base;
- R₁ represents OH;
- R₂ and R₃ represent, independently of each other, H or OH; and
- at least one of R₂ and R₃ represents H;

characterized in that the following steps are carried out:


- 1) a compound of formula (II) is condensed with the base B in order to obtain the compound of formula (III) according to the scheme



in which formulae (II) and (III):


- R'1 and R'2 have the meanings given for R₁ and R₂ except that when R₁ and R₂ represent OH, the said OH group is protected by a protecting group such as an acyl, benzoyl, benzyl or silyl group,
- R'3 represents a C₁ to C₅ alkyl group or a phenyl radical, which are optionally substituted,
- X is a leaving group such as Cl, Br, I or a C₁ to C₅ acyloxy or alkoxy group,
- B' is a purine or pyrimidine base B which is optionally appropriately protected,

2) the R'_3COO group at the 2' position is removed by deacetylation so as to obtain an OH group and a compound of formula




3) optionally, the OH group at the 2' position is removed; and
4) where appropriate, the R'_1 and R'_2 groups and the B' base are deprotected so as to obtain the compounds of formula (I).

2. (Currently Amended) ~~The method~~ according to Claim 1, characterized in that in the compounds (II) and (III), R'_3 represents a C_1 to C_5 alkyl group, preferably CH_3 .
3. (Currently Amended) ~~The method~~ according to Claim 1 or 2, characterized in that the compound (II), ~~di-O-acetylated at the 1, 2 position~~, in which X and R'_3COO represent an O-acetyl group, is prepared by acetolysis of ~~the a~~ 1,2-isopropylidene-L-xylofuranose compound of formula (V)



4. (Currently Amended) ~~The method~~ according to ~~one of~~ Claim[[s]] 1-to-3, characterized in that R'_2 and R'_3COO are different, in particular R'_2 is an O-benzoyl group and R'_3 is an alkyl group.
5. (Currently Amended) ~~The method~~ according to ~~one of~~ Claim[[s]] 1-to-4, characterized in that the compounds of formula (I) are prepared in which R_2 and R_3 represent H or OH.
6. (Currently Amended) ~~The method~~ according to ~~one of~~ Claim[[s]] 1-to-4, characterized in that the B represents one of the adenine, guanine, hypoxanthine, uracil, thymine or cytosine bases, ~~it being possible for~~ wherein these bases may be substituted especially by a halogen at the 5 position for cytosine and uracil.

7. (Currently Amended) ~~Method~~ The method according to claim 1 for the preparation of a compound of formula (I) in which B is cytosine according to one of ~~Claims 1 to 6~~, characterized in that a compound of formula (I) is prepared in which B is uracil according to the method of ~~Claims 1 to 6~~ and the uridine derivative is converted to a compound of Formula I in which B is cytosine cytidine derivative by converting uracil to cytosine.
8. (Currently Amended) ~~Stereoisomeric~~ A stereoisomeric β -L-pentofuranonucleoside compounds corresponding to the following formula



in which

- B has the meaning given in one of Claims 1 and 6 , R₁ represents OH and,
 - either R₂ represents OH and R₃ represents H,
 - or R₂ represents H and R₃ represents OH.

9. (Currently Amended) ~~Compounds~~ The compound according to Claim 7, characterized in that B represents uracil, 5-fluorouracil, hypoxanthine, 5-fluorocytosine, guanine or adenine.
10. -11 (Canceled)
12. (Currently Amended) ~~Use of the~~ A method of treatment of a viral infection comprising administering a compound[[s]] according to one of Claims 8 or 9 to 11, as drugs.
13. (canceled)
14. (Currently Amended) ~~Use of the~~ compounds according to one of Claims 8 to 11, as an antiviral drug which is useful for the treatment of AIDS The method of claim 12 wherein the viral infection is HIV.
15. (Currently Amended) ~~Use of~~ The method of claim 12 wherein the compound is β -L-5-fluoro ddC according to Claim 14, as antiviral agent.
16. (Currently Amended) ~~Use of~~ The method of claim 14 wherein the compound is β -L-5-fluoro ddC according to Claim 14, as anti-HIV agent.
17. (New) The method according to Claim 1, characterized in that in the compounds (II) and (III), R'3 represents CH₃.